OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
–CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and…